426 related articles for article (PubMed ID: 28625716)
21. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
22. Preferred Conformation-Guided Discovery of Potent and Orally Active HIF Prolyl Hydroxylase 2 Inhibitors for the Treatment of Anemia.
Wu Y; Zhang L; Sun Z; Qiu X; Chen Y; Su K; Yang L; Du Z; Dong Y; Yang F; Li X; Zhang X
J Med Chem; 2023 Jul; 66(13):8545-8563. PubMed ID: 37367818
[TBL] [Abstract][Full Text] [Related]
23. ExActa HIF prolyl hydroxylase inhibitors-The new lifestyle drug?
Sciesielski LK; Kirschner KM
Acta Physiol (Oxf); 2019 Nov; 227(3):e13370. PubMed ID: 31465609
[No Abstract] [Full Text] [Related]
24. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia.
HoWangYin KY; Loinard C; Bakker W; Guérin CL; Vilar J; d'Audigier C; Mauge L; Bruneval P; Emmerich J; Lévy BI; Pouysségur J; Smadja DM; Silvestre JS
Stem Cells; 2014 Jan; 32(1):231-43. PubMed ID: 24105925
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes by Prolyl Hydroxylase Domain 2 Inhibitors via Hypoxia-Inducible Factor-
Takano H; Yamaguchi JI; Kato S; Hamada M; Tada M; Endo H
Drug Metab Dispos; 2021 Jan; 49(1):20-30. PubMed ID: 33087449
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
Marxsen JH; Stengel P; Doege K; Heikkinen P; Jokilehto T; Wagner T; Jelkmann W; Jaakkola P; Metzen E
Biochem J; 2004 Aug; 381(Pt 3):761-7. PubMed ID: 15104534
[TBL] [Abstract][Full Text] [Related]
28. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
Li J; Xie QH; You L; Xu NX; Hao CM
Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
[TBL] [Abstract][Full Text] [Related]
29. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression.
Stockmann C; Fandrey J
Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):968-79. PubMed ID: 17002676
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
Kim SY; Yang EG
Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
[TBL] [Abstract][Full Text] [Related]
33. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
Rawee P; Eisenga MF
Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823872
[TBL] [Abstract][Full Text] [Related]
34. Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1α by inhibiting prolyl-4-hydroxylase PHD2.
Hou P; Kuo CY; Cheng CT; Liou JP; Ann DK; Chen Q
PLoS One; 2014; 9(11):e113865. PubMed ID: 25420025
[TBL] [Abstract][Full Text] [Related]
35. Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations.
Semenza GL
Annu Rev Med; 2023 Jan; 74():307-319. PubMed ID: 35773226
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene.
Wu S; Nishiyama N; Kano MR; Morishita Y; Miyazono K; Itaka K; Chung UI; Kataoka K
Mol Ther; 2008 Jul; 16(7):1227-34. PubMed ID: 18500250
[TBL] [Abstract][Full Text] [Related]
37. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Sugahara M; Tanaka T; Nangaku M
Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
Ogawa C; Tsuchiya K; Maeda K
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769359
[TBL] [Abstract][Full Text] [Related]
39. Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation.
Takeda K; Fong GH
Hypertension; 2007 Jan; 49(1):178-84. PubMed ID: 17101841
[TBL] [Abstract][Full Text] [Related]
40. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
